Anticoagulant News and Research

RSS

‘Chicken Wing’ clue to stroke risk in atrial fibrillation

Patients with atrial fibrillation who have a Chicken Wing left atrial appendage morphology are less likely to have a stroke than those with other morphologies, research suggests.

6 Aug 2012

ABP, Alembic enter into development and license agreement for Accu-Break tablet technologies

Accu-Break Pharmaceuticals, Inc. announced today that it has entered into a development and license agreement with Alembic Pharmaceuticals Limited of Gujarat, India to develop new brand products that will use ABP's innovative Accu-Break tablet technologies.

6 Aug 2012

Study identifies 329 instances of potentially inappropriate prescribing in Irish older patients

Research published in the journal Age and Ageing, which studied nursing homes in the Munster region of Ireland, has found that a significant proportion of older patients have either been prescribed a potentially inappropriate medicine or they are not prescribed a medicine that would normally be beneficial.

26 Jul 2012

Low blood anticoagulant levels increase risk for VTE

Low plasma levels of antithrombin, protein C, and protein S significantly increase the risk for venous thromboembolism, Italian research shows.

25 Jul 2012

PAMAM G-3 actually prevents activation of the process that leads to thrombosis

A compound that mops up debris of damaged cells from the bloodstream may be the first in a new class of drugs designed to address one of medicine's most difficult challenges -- stopping the formation of blood clots without triggering equally threatening bleeding.

24 Jul 2012

HAS-BLED: Atrial fibrillation patients undergoing angioplasty can still take anticoagulants

Researchers say that oral anticoagulation could improve the prognosis of atrial fibrillation patients who undergo percutaneous coronary intervention, even if they have a high bleeding risk according to the HAS-BLED score.

19 Jul 2012

Combination of tPA and 3K3A-APC may effectively treat stroke

A team led by a physician-scientist at the University of Southern California (USC) has created an experimental drug that reduces brain damage and improves motor skills among stroke-afflicted rodents when given with federally approved clot-busting therapy.

18 Jul 2012

Johnson & Johnson second quarter sales decrease 0.7% to $16.5B

Johnson & Johnson today announced sales of $16.5 billion for the second quarter of 2012, a decrease of 0.7% as compared to the second quarter of 2011. Operational results increased 3.5% and the negative impact of currency was 4.2%.

17 Jul 2012

SLU professor to study how antithrombin might prevent premature death from heart disease

Alireza "Ray" Rezaie, Ph.D., professor of biochemistry and molecular biology at Saint Louis University School of Medicine, has received a $1.52 million NIH grant to study how the key blood clotting inhibitor antithrombin might be exploited to prevent premature death from heart disease.

12 Jul 2012

AF care ‘inadequate’

Cardiology experts are supporting a call for greater attention to diagnosis and management of atrial fibrillation in primary care to prevent strokes.

10 Jul 2012

Phase III darexaban results revealed

The direct oral factor Xa inhibitor darexaban is effective for the prevention of venous thromboembolism in Japanese patients undergoing major abdominal surgery, researchers find.

10 Jul 2012

Self-management of anticoagulants in elderly could be beneficial

Elderly patients who self-manage their oral anticoagulant treatment have a comparable treatment-related quality of life to those who undergo routine care, and may even experience higher treatment satisfaction, researchers say.

10 Jul 2012

JRD receives FDA priority review designation for XARELTO sNDAs to treat PE, DVT

Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental New Drug Applications (sNDAs) filed on May 2, 2012 for XARELTO (rivaroxaban), an oral anticoagulant, seeking new indications to treat patients with deep vein thrombosis (DVT), pulmonary embolism (PE), and to prevent recurrent DVT and PE.

9 Jul 2012

Health Canada approves AutoGenomics’ INFINITI PGx testing system

AutoGenomics, a leader in providing automated, molecular microarray testing solutions, announced today that they have received their first Health Canada Medical Device Class III approvals for their automated INFINITI Pharmacogenomic (PGx) testing system.

28 Jun 2012

‘Risky’ view of thrombolysis in subtherapeutic warfarin patients disputed

A study in JAMA challenges the view that intravenous thrombolysis is a particularly risky procedure in stroke patients with subtherapeutic international normalized ratios.

27 Jun 2012

‘Risky’ view of thrombolysis in subtherapeutic warfarin patients disputed

A study in JAMA challenges the view that intravenous thrombolysis is a particularly risky procedure in stroke patients with subtherapeutic international normalized ratios.

27 Jun 2012

Pfizer, Bristol-Myers Squibb receive FDA CRL for ELIQUIS NDA

Bristol-Myers Squibb Company and Pfizer announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for ELIQUIS (apixaban) for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

25 Jun 2012

Rensselaer Center for Stem Cell Research launches today

Ground-breaking research to advance the application of stem cells to address critical injuries and diseases will be taking place at Rensselaer Polytechnic Institute, in a new center funded by New York state and opened today.

From Thermo Fisher Scientific Inc. 23 Jun 2012

New scientific findings in anticoagulation for stroke prevention

New scientific findings in anticoagulation for stroke prevention are paving the way for updates to the European Society of Cardiology (ESC) Guidelines for the management of atrial fibrillation.

14 Jun 2012

Boehringer Ingelheim updates U.S. prescribing information for Pradaxa with FDA

Boehringer Ingelheim has today announced that it has updated the US prescribing information for Pradaxa (dabigatran etexilate) in alignment with the US Food and Drug Administration (FDA) to affirm that "Pradaxa 150mg twice daily was superior in reducing ischemic and hemorrhagic strokes relative to warfarin."

7 Jun 2012